SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Nephros Awaits Two Pending FDA Marketing Clearances
DVA
|
|
|
+17.75%
in
104 days
Nephros (OTC:NEPH) (NEPH.OB) is a medical device company which originally developed HDF products for ESRD patients and has since expanded its core business to include water filtration, including FDA marketing clearance for the Company’s DSU filters in early July. A summary of the Company’s products includes the following: <o:p> </o:p> http://biomedreports.com/articles/most-popular/3391-nephros-a... <o:p> </o:p> <> 1.) The OLpur MDHDF filter series is already sold in Europe and currently consists of the Company’s MD190 and MD220 diafilters, which represents <><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Rockwell Medical: Improving Margins, SFP Key to Future
DVA
|
|
|
+10.41%
in
126 days
(closed on 07/29/09)
By Mike Havrilla on 3/25/09 at BioMedReports.com <> In mid-March, Rockwell Medical Technologies (RMTI) reported 4Q and FY08 results which included revenue of $13.5M (up 13.3% from year-ago quarter) and $51.6M (up 20% compared to 2007). The net losses were ($3M) and ($7.9M) for 4Q and FY08, respectively. Despite solid sales growth, RMTI has posted losses as margins have suffered due to higher raw material/fuel costs and other investments in personnel, information technology (IT), and clinical development...
|
A New Global Healthcare Composite Index
DVA
|
|
|
-1.59%
in
121 days
(closed on 03/25/09)
<> 
The accompanying table [click to enlarge or download] presents the top five rated companies with market caps of at least $250M from each of the 10 new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 500 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 50 top rated companies on an equal weight basis from each of the 10 new healthcare indexes as an alternative strategy to existing health composite ETFs with highly correlated returns and over-weight exposure to th...
|
Hospitals Hoping for Increased Insurance Coverage
DVA
|
|
|
-14.35%
in
15 days
(closed on 11/23/08)
<> 
The combination of a bad economy and rising unemployment is contributing to unpaid bills and operating losses at U.S hospital companies such as Tenet Healthcare (THC), which missed analyst estimates last week by 3-cents with an adjusted 6-cent per share loss and lowered its full-year and 2009 guidance for EBITDA. Tenet's allowance for doubtful accounts increased 5.8% to $163M at hospitals run by the Company for over a year.
With Tenet trading all-time lows, several insiders were buying a combined 160...
|
From the Blogosphere
DaVita Tops Zacks Estimate – Analyst Blog
|
|
|
DaVita Inc. (DVA) reported third quarter net income of $110.9 million or $1.06 per share, which was better than the Zacks Consensus Estimate of 99 cents. The company earned $93.9 million or 89 cents in the comparable quarter of 2008.
Revenues for the quarter came in at $1.57 billion, which reflected an 8.3% increase over the year-ago quarter. According to segments, revenues from the Dialysis and Related Lab Services segment for the quarter came in at $1.49 billion as against $1.38 billion in the prior-year quarter. Other - Ancillary Services and Strategic Initiatives segment generated reve...
|
DaVita Is Looking Healthy - Barron's
The nation's second-largest chain of kidney dialysis clinics, DaVita (DVA) hasn't seen much of a bump from the market's recent rally. But with profits climbing and the U.S. population aging, Barron's Johanna Bennett says DaVita is a compelling buy. 
|
Notable Analyst Rating Changes 4/27: BUCY, JOYG, MMM, NFLX Upgraded; BNI, HON, MAR, SONC Downgraded
UPGRADES:Goldman Sachs upgrades Bucyrus International (Nasdaq: BUCY) and Joy Global (Nasdaq: JOYG) from Neutral to Buy, with a $23 and $32 price target respectively.Barclays upgrades 3M (NYSE: MMM) from Underweight to Equalweight. Price target increased from $41 to $62. Citi upgrades Netflix Inc (Nasdaq: NFLX) from Hold to Buy. Price target increased from $37 to $52. Click here for more color.UBS upgrades AstraZeneca (NYSE: AZN) from Neutral to Buy. Piper Jaffray upgrades DaVita Inc. (NYSE: DVA) from Neutral to Buy. Price target $57. Click here for the full report. For daily real-time Upgr...
|
FDA Calendar: High Hopes for Amgen's Bone Drug
|
|
|
The accompanying table [click to enlarge] includes an updated FDA calendar of 69 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with seven companies listed in red with overdue decisions. Since my last update, the following FDA action has occurred:
1.) Amgen (AMGN) filed a BLA for bone drug denosumab in the following two indications: the treatment + prevention of osteoporosis in post-menopausal women and the treatment + prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer, with the potential for...
|
FDA Calendar: High Hopes for Amgen's Bone Drug
|
|
|
The accompanying table [click to enlarge] includes an updated FDA calendar of 69 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with seven companies listed in red with overdue decisions. Since my last update, the following FDA action has occurred:
1.) Amgen (AMGN) filed a BLA for bone drug denosumab in the following two indications: the treatment + prevention of osteoporosis in post-menopausal women and the treatment + prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer, with the potential for...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Davita Inc.
- Answers.com
